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ABSTRACT
Objective: The aim of this study was to carry out adverse drug reactions (ADRs) monitoring in various departments of a tertiary care teaching hospital.
Methods: A cross-sectional study was conducted on ADRs reported in the hospital from December 2012 to May 2013 after obtaining Institutional 
Ethics Committee approval.
Results: A total of 40 ADRs were reported, 47.50% were males and 52.50% were females. The female adult population was 45%. The majority of ADRs 
were due to antimicrobial agents especially beta-lactam antibiotics (42.5%) followed by NSAIDs (7.50%). A maximum number of patients (75%) 
were reported with dermatological manifestations. The department of medicine reported the highest number of ADRs (37.5%). As per Naranjo’s 
probability scale, 62.5% reports were assessed as probable. 62.5% reports were documented as mild according to Modified Hartwig’s criteria for 
severity assessment.
Conclusion: This study was done to sensitize the practicing physicians on the importance of adverse drug monitoring and reporting.
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INTRODUCTION
Drug safety is a major concern in the field of medicine. Adverse drug 
reaction (ADR) reports can indicate the important safety issues on drug 
treatment. Documentation of these reports can direct the changes in the 
pattern of prescribed drugs and it could even lead to the withdrawal of 
the drug from the market. Serious adverse events can cause admission 
to hospital, prolongation of hospitalization, increase in investigations 
or treatment costs, poor work adherence, birth defects, and danger 
to life leading to death. ADRs may act through the same physiological 
and pathological pathways as in different diseases; hence, they are 
difficult and sometimes impossible to distinguish the features. The 
World Health Organization’s (WHO) defined the ADR as “response to 
a drug, which is noxious and unintended, and which occurs at doses 
normally used in man for prophylaxis, diagnosis or therapy of disease, 
or for the modification of physiological function’ [1]. The safety of 
an approved drug is examined extensively in preclinical studies and 
in all the human clinical trials. Even in large clinical trials which are 
conducted for FDA approval, not all safety issue will be recognized. In 
preclinical animal studies, it is insufficient to predict the human safety. 
The rare side effect cannot be detected during the clinical trials in 
human as it involves limited subjects, which could be explored during 
postmarketing surveillance [2]. Thalidomide tragedy provoked the 
establishment of drug monitoring systems. It took more than a decade 
to ban the drug Terfenadine for its serious side effect of fatal cardiac 
arrhythmia [3]. Most of the drugs do not cause adverse drug effect; 
even those reaction which had occurred might be attributed to their 
individual pharmacogenomic pattern. Pharmacovigilance Programme 
of India (PvPI) 2014 stated that 6.7% of patients had serious adverse 
events. Similar studies have documented that hospital admissions due 
to ADR were 3.4%, hospital readmissions 3.7%, and mortality 1.8% [4]. 
Adverse reactions are recognized as the fourth-leading cause of death 
in the developed world. Although India is the third largest medicine 
market of the world, it had documented only 2% of global ADRs until 
2013. PvPI increased the ADRs monitoring centers from 90 to 150 
including the private hospitals, which led to increasing in ADR reporting. 
India became the first country in reporting the Individual Case Safety 
Reports of more than one lakh to Vigiflow, Uppsala Monitoring Centre. 
It has to be made mandatory for all health-care providers such as 
physicians, dentists, nurses, pharmacists to report ADRs as part of their 
professional responsibility, even if they are doubtful about the specific 
relationship with the given medication. One of the most important 
ways to prevent adverse drug events is to share information since all 
medication errors are preventable which can be achieved by sensitizing 
awareness among the healthcare professionals to report and follow-up 
the events.
METHODS
A cross-sectional study was conducted for a duration of 6 months 
from December 2012 to May 2013 at SRM Medical College Hospital 
and Research Centre after obtaining the approval of the Institutional 
Ethics Committee. ADR details were collected from the patient 
after the oral informed consent. During this period, routine ward 
rounds were carried out and awareness was given to all health-care 
professionals for the voluntary reporting system. The ADR information 
was documented based on the treating physician’s report. Patient 
information such as age, gender, IP number, weight, diagnosis, relevant 
investigations, and drug information such as name of the drug, dose, 
route of administration, frequency of administration, duration of 
therapy, types of ADR, treatment and outcome of the reaction were 
collected and the data were documented in the study proforma; each 
reported patients were assessed individually. Causality assessment 
was done based on Naranjo’s probability scale. The total score was 
calculated based on the score and it was categorized as certain 
(score >9), probable (score 5-8), and possible (score1-4) [5]. Modified 
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Hartwig’s criteria were used to assess the severity of ADRs into seven 
levels: Levels 1 and 2 was classified as mild category; levels 3 and 4 
as moderate category; levels 5, 6, and 7 were grouped as the severe 
category.
RESULTS
During the period of this study, 40 ADRs were reported. Of these 
19 (47.50%) were males and 21(52.50%) were females (Fig. 1).
The maximum number of ADRs which were reported in this study was 
adult females (45%) of age group 18-60 years followed by adult males 
(27.5%) of the same age group (Fig. 2).
Maximum ADRs were reported from Department of Medicine (37.5%) 
followed by surgery (25%) and otorhinolaryngology (10%) (Fig. 3).
42.5% ADRs were due to beta-lactam antibiotics followed by 
fluoroquinolone and metronidazole (Fig. 4).
Based on the severity of the reaction, most of the cases (62.5%) 
were mild (Fig. 5). Causality assessment showed 62.5% of cases in 
the probable category, only one patient had an assessment as certain 
(2.5%) (Fig. 6).
About 75% of the ADR cases had skin lesions like urticaria and 
erythematous rash due to cephalosporin’s group of antibiotics and 
NSAIDs (Tables 1 and 2).
DISCUSSION
India holds the second place in the global population and the third 
place in drug marketing but only 2% ADRs are reported. This study 
was done to emphasize the need for ADR documentation. Out of the 
40 patients reported during this study, there was an insignificant 
increase in prevalence among female (52.5%) than male (47.5%) 
which was similar to a study done by Saravanan et al. [6]. When we 
analyze according to the age group, the prevalence was more in the 
female adult population (45%) compared to adolescent and elderly 
females which could be explained by the fact that women are more 
into polypharmacy, drug intake and prone for more sensitivity toward 
medication [7,8]. Due to more patient inflow, the majority of incidence 
were found to be in general medicine and general surgery department 
in concurrence with the observation done by Vora et al. [9] Among 
the ADRs, major proportions of adverse reactions were seen with 
Beta-lactam antibiotics which were similar to the observation by 
Fig. 1: Gender distribution in reported adverse drug reactions
Fig. 2: Age distribution in reported adverse drug reactions
Fig. 3: Adverse drug reactions reported from various departments
Fig. 4: Drugs in reported adverse drug reactions
Fig. 5: Severity of reported adverse drug reactions (in percentage)
Fig. 6: Causality assessment in reported adverse drug reactions
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Rodriguez-Pena et al. as well as by Raut et al. [10,11] Since beta-lactam 
is one of the most common antibiotics used by the practicing doctors 
[12]. In this study, most of the reactions were mild (62.5%) followed 
by moderate (35%) and only 3% showed severe reaction similar ratio 
of reactions were also documented in a study by Shamna et al. [13] 
The severity of the reactions were assessed based on the Modified 
Hartwig’s criteria for severity assessment, patients who had reactions 
were advised to stop the drug immediately, those who had mild to 
moderate reactions were treated with antihistamine and steroids 
as per their need, whereas the patient who had severe reactions got 
hospitalized and all the patients who had ADRs recovered completely 
after treatment. They were given counseling to report to their treating 
physicians about their drug history to avoid such reactions in future. 
According to the Naranjo scale, the causality assessment of the reported 
ADRs in this study revealed that 62.5% of reactions were recognized as 
Probable, in accordance with a study done by Mandavi et al. which had 
reported 88.6% as probable [14,15]. Only one patient had the causality 
assessment as certain for drug ciprofloxacin which was ascertained by 
rechallenge by the patient who took the medication without consulting 
the doctor using the old prescription, but this time the itching was very 
much pronounced than the previous episode hence she had come to 
the hospital for treatment.
When we analyze the presentation of reactions, almost 75% showed 
cutaneous reactions like urticaria, erythematous rashes, this was in 
correlation with the study done by Jose et al. and Chawla et al. [16]. 
When we observed the type of reactions caused by drugs it was noted 
that most of the cephalosporins group of drugs caused urticaria, it 
was also observed that NSAIDs drugs developed erythematous rashes, 
one patient had developed chest tightness following administration 
of contrast dye iopamide, and another patient had rigor following 
treatment with vancomycin [17]. Cutaneous ADRs were common with 
antimicrobials (62.5%) followed by non-steroidal anti-inflammatory 
drugs (18.75%) which were in sequence to a study done by Sharma 
et al. who had claimed that 40% and 35% of the cutaneous ADRs were 
due to antimicrobial and NSAIDs, respectively[18]. Many studies have 
attributed that altered liver and renal function tests may predispose 
to severe cutaneous ADRs because of abnormal drug metabolism and 
clearance from the body [19].
CONCLUSION
The significance of this study is to emphasize the awareness to the 
health-care providers on vigilant monitoring of ADRs and promptly 
reporting the same so as to prevent the occurrence of the reactions 
in the vulnerable population. Frequent pharmacovigilance programs 
should be initiated to sensitize the health-care workers on the 
importance of reporting the ADRs. Above all, proper counseling for the 
patient to inform about their previous drug allergy if any, to the treating 
physician and also should be emphasized to avoid self-medications. 
A systematic comprehensive monitoring and documentation of ADRs 
can curtail many untoward reactions in patient care and will lead to an 
effective drug administration.
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ADRs: Adverse drug reactions
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